FLGT vs. ADUS, VCYT, PACS, WGS, LFST, ARDT, PGNY, NHC, GRAL, and TDOC
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Addus HomeCare (ADUS), Veracyte (VCYT), PACS Group (PACS), GeneDx (WGS), LifeStance Health Group (LFST), Ardent Health (ARDT), Progyny (PGNY), National HealthCare (NHC), GRAIL (GRAL), and Teladoc Health (TDOC). These companies are all part of the "healthcare" industry.
Fulgent Genetics vs. Its Competitors
Addus HomeCare (NASDAQ:ADUS) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.
Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.
Addus HomeCare presently has a consensus target price of $142.57, indicating a potential upside of 27.46%. Fulgent Genetics has a consensus target price of $24.00, indicating a potential upside of 19.64%. Given Addus HomeCare's stronger consensus rating and higher possible upside, equities analysts clearly believe Addus HomeCare is more favorable than Fulgent Genetics.
95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 4.6% of Addus HomeCare shares are held by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Addus HomeCare had 6 more articles in the media than Fulgent Genetics. MarketBeat recorded 8 mentions for Addus HomeCare and 2 mentions for Fulgent Genetics. Addus HomeCare's average media sentiment score of 0.49 beat Fulgent Genetics' score of 0.00 indicating that Addus HomeCare is being referred to more favorably in the media.
Addus HomeCare has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Addus HomeCare has a net margin of 6.52% compared to Fulgent Genetics' net margin of -13.94%. Addus HomeCare's return on equity of 9.23% beat Fulgent Genetics' return on equity.
Summary
Addus HomeCare beats Fulgent Genetics on 14 of the 17 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:FLGT) was last updated on 7/4/2025 by MarketBeat.com Staff
